(A) Schematic of the MV4-11–luciferase or THP-1–luciferase cell-derived xenograft (CDX) model of AML. (B) In vivo leukemic growth as measured by whole-body luminescence of MV4-11–luciferase cells (left) or THP-1–luciferase cells (right) in CDX mice treated with 10 mg/kg isotype control (gray) or NC525 (red). n = 8 mice per group. P values determined by 2-way ANOVA. (C and D) MV4-11 cell counts (C) or percent dead MV4-11 cells (D) in the blood, spleen, or BM of CDX mice treated with vehicle control (gray) or 10 μg/mL NC525 (red). (E) Total cell counts or mouse (M) CD45⁺ cell counts in the BM of CDX mice treated with vehicle control (gray) or 10 μg/mL NC525 (red). n = 9–10 mice per group. P values determined by Student’s t test. Data are shown as the mean ± SEM. (F) Representative histograms of LAIR-1 cell surface expression on the indicated cell lines. (G) Schematic of CDX model systems to test the inhibition of leukemic growth as a function of LAIR-1 expression. (H) Percent inhibition of MV4-11-LAIR-1–knockout (green), MV4-11-LAIR-1–wild-type (purple), or MV4-11-LAIR-1–overexpression cell growth in vivo (normalized to the mean of the respective isotype controls) after treatment with 10 mg/kg NC525 (left) and plotted against LAIR-1 geometric mean fluorescence intensity (gMFI) (right). (I) Percent inhibition of MV4-11 growth fit to a logarithmic regression curve of LAIR-1 expression. n = 9 mice per group.